Has Firas Jafri, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,716 in general payments to Firas Jafri, MD across 111 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Firas Jafri, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Firas Jafri, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Firas Jafri, MD

Hematology & Oncology · Valhalla, NYNPI 1376079442

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.3% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,616, 3.2 times the $512 reported in 2022.

$3,716in general payments, 2019–2025

Across 111 payments — averaging $33.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$696
AstraZeneca$640
Pfizer$356
Daiichi Sankyo Inc.$278
Pharmacosmos Therapeutics Inc.$224
Regeneron Healthcare Solutions, Inc.$176
plus $1K from 23 others

What the payments were for

Food & beverage$3,54195%
Education$1755%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	13	$696
AstraZeneca	15	$640
Pfizer	19	$356
Daiichi Sankyo Inc.	7	$278
Pharmacosmos Therapeutics Inc.	3	$224
Regeneron Healthcare Solutions, Inc.	3	$176
Adaptive Biotechnologies Corporation	2	$156
Novartis	6	$149
Intuitive Surgical	1	$123
Bristol Myers Squibb	5	$120
Merck	5	$118
Incyte Corporation	4	$89
AbbVie	3	$69
Array Biopharma Inc	3	$66
Sanofi	2	$54
Bayer	2	$48
Taiho Oncology, Inc.	2	$48
Tersera Therapeutics LLC	2	$40
Eisai Inc.	2	$37
Astellas Pharma US Inc	2	$34
Genentech USA, Inc.	2	$33
Johnson & Johnson	1	$26
GSK	1	$24
ADC Therapeutics America, Inc.	1	$22
Geron Corporation	1	$21
Janssen Scientific Affairs, LLC	1	$21
Jazz Pharmaceuticals Inc.	1	$16
Myriad Genetic Laboratories, Inc.	1	$16
Accord Healthcare, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,716 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024

$14,375

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ImbruvicaIbrutinib	30	$537,544
Anastrozole	16	$131

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Valhalla

Michael SchusterNew York$1.6M
Charles SawyersNew York$1.6M
Manuel Hidalgo-MedinaNew York$1.4M
Francis ArenaLake Success$1M
Sanjeev JainEast Patchogue$971K
Ross LevineNew York$968K
Perry CookBrooklyn$803K
Mihir RavalAlbany$767K
Joshua SabariNew York$761K
Gail RobozNew York$738K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →